Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin

  • Authors:
    • Sun Young Kim
    • Hwang Phill Kim
    • Yu Jung Kim
    • Do Youn Oh
    • Seock-Ah Im
    • Dongsoon Lee
    • Hyun-Soon Jong
    • Tae-You Kim
    • Yung-Jue Bang
  • View Affiliations

  • Published online on: January 1, 2008     https://doi.org/10.3892/ijo.32.1.89
  • Pages: 89-95
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

HER2 has been found to be amplified in 10-20% of gastric cancers, and is correlated with poor outcome. The aims of this study were to recognize HER2 amplification in gastric cancer cell lines via fluorescence in situ hybridization and to evaluate the growth inhibitory effect of trastuzumab in HER2-amplified cell lines. To elucidate the mechanism of the growth inhibition, we performed cell cycle analysis and immunoblotting of downstream molecules. We also conducted drug interaction studies of trastuzumab with other chemothera-peutic agents. HER2 amplification was newly identified only in SNU-216 cells, and trastuzumab moderately inhibited the growth of SNU-216 cells and positive controls. Trastuzumab-mediated G1 arrest occurred with increased expression of p27KIP1 and decreased cyclins. Phosphorylation of HER2 and downstream molecules, STAT3, AKT, and ERK, was also inhibited by trastuzumab. Treatment of SNU-216 cells with trastuzumab plus cisplatin resulted in a synergistic inhibitory effect, whereas treatment of SNU-216 cells with trastuzumab plus 5-FU, or trastuzumab plus oxaliplatin produced an additive effect. These results suggest that trastuzumab combined with chemotherapeutic agents can be active against gastric cancer with HER2 amplification.

Related Articles

Journal Cover

January 2008
Volume 32 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim SY, Kim HP, Kim YJ, Oh DY, Im S, Lee D, Jong H, Kim T and Bang Y: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008.
APA
Kim, S.Y., Kim, H.P., Kim, Y.J., Oh, D.Y., Im, S., Lee, D. ... Bang, Y. (2008). Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. International Journal of Oncology, 32, 89-95. https://doi.org/10.3892/ijo.32.1.89
MLA
Kim, S. Y., Kim, H. P., Kim, Y. J., Oh, D. Y., Im, S., Lee, D., Jong, H., Kim, T., Bang, Y."Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin". International Journal of Oncology 32.1 (2008): 89-95.
Chicago
Kim, S. Y., Kim, H. P., Kim, Y. J., Oh, D. Y., Im, S., Lee, D., Jong, H., Kim, T., Bang, Y."Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin". International Journal of Oncology 32, no. 1 (2008): 89-95. https://doi.org/10.3892/ijo.32.1.89